Company Overview and News

MWE share trade to be suspended on Sept 20, 2018

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): Trading of MWE Holdings Bhd shares will be suspended on Thursday (September 20, 2018) to facilitate the implementation of the diversified company's selective capital reduction and repayment (SCR) exercise.
3921 BSMAF 1818

1MDB Update: Extradition move for Jho Low next step for Malaysia

2018-09-03 theedgemarkets
MALAYSIA finally moved against Jho Low, or Low Taek Jho, with the filing of criminal charges against him, albeit in absentia, on Aug 24.

10 things to know about Malaysian businessman Jho Low

2018-07-13 theedgemarkets
(July 12): The hunt for fugitive businessman Low Taek Jho, wanted in a global corruption probe in connection with the 1Malaysia Development Bhd (1MDB) state fund, is now shifting to the West Indies islands.
3921 NYTAB

The Week Ahead: Eyes on Trump-Kim rendezvous, FOMC hike, full Cabinet line-up and World Cup 2018

2018-06-11 theedgemarkets
The world will be watching two of the greatest shows this week — the momentous meeting between US President Donald Trump and North Korean leader Kim Jong-un at the Capella Hotel in Singapore on June 12, and the kick-off of the 2018 Fifa World Cup in Moscow on Thursday, just ahead of the Hari Raya celebrations on Friday.
9717 5216 1201 3921 0091 CPICQ FUTR 5085 0151 8311 0152 LIIHF

Trading ideas: MWE, BToto, Wah Seong, Vizione

KUALA LUMPUR: MWE Holdings Bhd , Berjaya Sports Toto Bhd , Wah Seong Corp BHd and Vizione Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
1562 3921

MWE surges on privatisation offer

PETALING JAYA: Garment maker MWE Holdings Bhd surged by 33 sen or 25.38% to RM1.63 as trade closed yesterday, largely on the back of a privatisation offer from tycoon Tan Sri Surin Upatkoon (pic).
3921 BSMAF 1818

MWE seeks suspension

PETALING JAYA: MWE Holdings Bhd has requested that its securities be suspended from trading, pending the release of a material announcement.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...